Regulatory Affairs Syndicator

Regulatory Affairs Updates and Bulletins by Joe Schwoebel

  • Blog
  • Warning Letters
  • FDA Links
  • Resource
  • Register


« UPDATE 1-Merck may wait to 2013 in US for cholesterol drug - Reuters
Commentary: Toward a Fuller Understanding of Business Risks in China - US-China Today »

Ligand says FDA extends blood-clot drug review - Forbes

Published by Google Inc. June 20th, 2008 in Google FDA News, Regulatory Affairs

Ligand says FDA extends blood-clot drug review
Forbes, NY - 12 hours ago
AP 06.20.08, 4:31 PM ET Drug developer Ligand Pharmaceuticals Inc. said after the bell Friday the Food and Drug Administration will take an additional three …
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority … FOXBusiness
GSK Update on FDA Review of Promacta(R) (Eltrombopag) Earthtimes (press release)
GlaxoSmithKline: FDA extends priority review period for Promacta Trading Markets (press release)
all 25 news articles


Search



Regulatory Affairs Syndicator is powered by WordPress 2.0.3 and K2 Beta Two r167 by Michael and Chris
RSS Entries and RSS Comments